

<b>Reference:</b>	FOI.18971.25
<b>Subject:</b>	Pharmacy and prescribing practice
<b>Date of Request:</b>	27 November 2025

**Your request and our response**

I would be grateful if you could send me information related to durvalumab (Imfinzi) and trastuzumab deruxtecan (Enhertu). Please include all hospitals in your organisation.

Hywel Dda University Health Board (UHB) is unable to provide you with some of the requested information as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding the following details under Section 40(2) of the FoIA:

- The information requested for question 8 broken down by cancer type due to the low number of cases (less than 5), or the ability to calculate the redacted figures from those greater than 5
- The figures in the table for question 14 has been replaced with an asterisk (\*) due to the low numbers of cases (less than 5)

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

However, the UHB provides the information it holds below as requested.

1. Does the aseptic unit at your organisation employ vial-sharing for durvalumab (Imfinzi)?

	<b>Yes / No</b>
Employs vial-sharing for durvalumab (Imfinzi)	No

2. In the past 12 months was durvalumab (Imfinzi) administered as the following actual doses?

<b>1 December 2024 to 30 November 2025</b>	<b>Yes / No</b>
1,500 mg	Yes
10 mg / kg	No
20 mg / kg	No

3. In the past 12 months was durvalumab (Imfinzi) made up for administration to patients at an on-site aseptic unit?

<b>1 December 2024 to 30 November 2025</b>	<b>Yes / No</b>
On-site aseptic unit	Yes

4. In the past 12 months was durvalumab (Imfinzi) made up for administration to patients at an external aseptic unit?

<b>1 December 2024 to 30 November 2025</b>	<b>Yes / No</b>
External aseptic unit – based at another hospital	No
External aseptic unit – from a third supplier	Yes

5. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of durvalumab (Imfinzi) in the past 12 months.

Not applicable.

6. How many patients were treated with durvalumab (Imfinzi) between Jul and Sep 2025, or latest 3 months for which data is available?

<b>1 July to September 2025</b>	
<b>Number of patients</b>	15

7. How many patients were treated with durvalumab (Imfinzi) within each of bands in the national dose banding table overleaf between Jul and Sep 2025?

<b>1 July to September 2025</b>				
<b>Band range (mg)</b>			<b>Band dose (mg)</b>	<b>Number of patients</b>
<b>From ≥</b>	<b>To (A) &lt;</b>	<b>To (B) ≤</b>		
189.74	219.09	219.08	200	0
219.09	268.33	268.32	240	0
268.33	328.63	328.62	300	0
328.63	388.84	388.83	360	0
388.84	458.26	458.25	420	0
458.26	547.72	547.71	500	0
547.72	648.07	648.06	600	0
648.07	771.36	771.35	700	0
771.36	921.95	921.94	850	0
921.95	1058.30	1058.29	1000	0
1058.30	1178.47	1178.46	1120	0
1178.47	1363.82	1363.81	1240	0
1363.82	1596.87	1596.86	1500	15
1596.87	1843.91	1843.90	1700	0

[NHS commissioning » Chemotherapy dose banding](#)

8. How many patients were treated with durvalumab (Imfinzi) for the following types of cancer between Jul and Sep 2025, or latest 3 months for which data is available?

<b>1 July to September 2025</b>	
<b>Type of Cancer</b>	<b>Number of patients</b>
Non-small Cell Lung Cancer	An exemption under Section 40 has been applied.
Biliary Tract Cancer	
Small Cell Lung Cancer	
Hepatocellular Carcinoma	
Endometrial Cancer	
Muscle Invasive Bladder Cancer	
Other (please specify)	

9. Does the aseptic unit employ vial-sharing for trastuzumab deruxtecan (Enhertu)?

	Yes / No
Employs vial-sharing for trastuzumab deruxtecan (Imfinzi)	No

10. In the past 12 months was trastuzumab deruxtecan (Enhertu) administered as the following actual doses?

1 December 2024 to 30 November 2025	Yes / No
6.4 mg / kg	No
5.4 mg / kg	Yes
4.4 mg / kg	No
< 4.4 mg / kg	Yes

11. In the past 12 months was trastuzumab deruxtecan (Enhertu) made up for administration to patients at an on-site aseptic unit?

1 December 2024 to 30 November 2025	Yes / No
On-site aseptic unit	Yes

12. In the past 12 months was trastuzumab deruxtecan (Enhertu) made up for administration to patients at an external aseptic unit?

1 December 2024 to 30 November 2025	Yes / No
External aseptic unit – based at another hospital	No
External aseptic unit – from a third supplier	Yes

13. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of trastuzumab deruxtecan (Enhertu) in the past 12 months.

Not applicable.

14. How many patients were treated with trastuzumab deruxtecan (Enhertu) within each of bands in the national dose banding table below between Jul and Sep 2025?

1 December 2024 to 30 November 2025				
Band Range (mg)			Band Dose (mg)	Number of patients
From ≥	To (A) <	To (B) ≤		
95.92	103.92	103.91	100.00	0
103.92	111.93	111.92	108.00	0
111.93	121.85	121.84	116.00	0
121.85	135.77	135.76	128.00	0
135.77	151.79	151.78	144.00	*
151.79	169.71	169.70	160.00	0
169.71	189.74	189.73	180.00	0
189.74	209.76	209.75	200.00	0
209.76	229.78	229.77	220.00	*
229.78	249.80	249.79	240.00	*
249.80	269.82	269.81	260.00	*

269.82	289.83	289.82	280.00	*
289.83	309.84	309.83	300.00	*
309.84	339.41	339.40	320.00	0
339.41	379.47	379.46	360.00	*
379.47	419.52	419.51	400.00	*
419.52	459.57	459.56	440.00	*
459.57	489.90	489.89	480.00	0
489.90	519.62	519.61	500.00	0
519.62	569.21	569.20	540.00	0
569.21	619.68	619.67	600.00	0
619.68	669.33	669.32	640.00	0
669.33	719.72	719.71	700.00	0
719.72	769.42	769.41	740.00	0
769.42	848.53	848.52	800.00	0
848.53	948.68	948.67	900.00	0

[NHS commissioning » Chemotherapy dose banding](#)